| Bioactivity | PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits PD-1/PD-L1 proteins (IC50=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8+ cell infiltration[1]. |
| Invitro | PD-1/PD-L1-IN-44 显示出非特异性毒性 (IC50=>20 μM (MDA-MB231), >20 μM (H1299), >20 μM (HCT116), >20 μM (A549))[1]。PD-1/PD-L1-IN-44 (10 μM; 48 h) 有效抑制 A549/PBMC T 细胞中 A549 细胞的增殖能力，抑制率甚至达到 76.5%[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PD-1/PD-L1-IN-44 相关抗体: Immunofluorescence[1] Cell Line: |
| In Vivo | PD-1/PD-L1-IN-44 (10 mg/kg; i.p.; 每天一次，持续 21 天) 显著抑制了 4T1 模型 小鼠的肿瘤生长[1]。该药物的溶解制剂为 5% 二甲基亚砜，10% 蓖麻油，85% 生理盐水 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C34H30N2O6 |
| Molar Mass | 562.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang Y, et al. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1. Eur J Med Chem. 2024 May 5;271:116433. |